• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

    2/14/23 4:51:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNXT alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

     

    RENOVORX, INC.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

     

     

    75989R 107

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 75989R 107    

     

    1

    NAME OF REPORTING PERSON:

     

    Ramtin Agah

       

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY:

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    152,872

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    152,872

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    152,872 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ☐

     

    11 1.7% (2)
    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

     

      (1) Includes (i) 6,477 shares of common stock held of record by Ramtin Agah (the “Reporting Person”); (ii) 145,100 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2022 to the Reporting Person; and (iii) 1,295 shares of common stock that are issuable upon exercise of outstanding warrants within 60 days of December 31, 2022 to the Reporting Person.
         
      (2) Based on 9,097,701 shares of the Issuer’s common stock outstanding as of November 8, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission on November 14, 2022.

     

     

     

     

    Item 1
       
      (a) Name of Issuer:
       
      RenovoRx, Inc.
       
      (b) Address of Issuer’s Principal Executive Offices:
       
      4546 El Camino Real, Suite B1
      Los Altos, California 94022
       
    Item 2
       
      (a) Names of Persons Filing:
       
      Ramtin Agah (the “Reporting Person”)
       
       (b) Address or principal business office or, if none, residence:
       
      The principal business office address of the Reporting Person is:
       
      c/o RenovoRx, Inc.
      4546 El Camino Real, Suite B1
      Los Altos, California 94022
       
      (c) Citizenship:
       
      Reference is made to the response to item 4 on page 2 of this Schedule 13G (this “Schedule”), which responses are incorporated herein by reference.
       
      (d) Title and Class of Securities:
       
      Common Stock, par value $0.0001 per share.
       
      (e) CUSIP No.:
       
      75989R 107

     

     

     

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable.
       
    Item 4. Ownership
       
      Reference is hereby made to the responses to items 5-9 and 11 of page 2, which responses are incorporated herein by reference.
       
    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
       
    Item 6. Ownership of More than 5 Percent on Behalf of Another Person
       
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable.
       
    Item 10. Certifications
       
      Not applicable.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023

     

      /s/ Ramtin Agah
      Ramtin Agah, MD

     

     

    Get the next $RNXT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RNXT

    DatePrice TargetRatingAnalyst
    11/1/2021$16.00Buy
    Roth Capital
    10/6/2021$15.00Buy
    Maxim Group
    More analyst ratings

    $RNXT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

    MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer. The designation was issued by the FDA's Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and commonly used chemotherapy. As RenovoRx continues to advan

    5/28/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

    Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects MOUNTAIN VIEW, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that an abstract from a pharmacokinetic (PK) and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial has been published online in connection with the 2026

    5/26/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

    MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai and Chief Financial Officer Mark Voll will participate in the Alliance Global Partners (AGP) Annual Healthcare Company Showcase, hosted by Scott Henry, AGP's Managing Director and Senior Healthcare Analyst, on May 20, 2026. Mr. Bagai and Mr. Voll will discuss RenovoRx's commercial progress, including record first-quarter 2026 revenue from RenovoCath as a standalone drug-d

    5/19/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on RenovoRx with a new price target

    Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

    11/1/21 11:49:10 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on RenovoRx with a new price target

    Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

    10/6/21 8:24:28 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Voll Mark bought $19,690 worth of shares (25,000 units at $0.79), increasing direct ownership by 21% to 142,380 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    5/21/26 7:00:14 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Voll Mark bought $19,690 worth of shares (25,000 units at $0.79), increasing direct ownership by 21% to 142,380 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    5/21/26 7:00:14 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bagai Shaun

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/7/26 8:00:06 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Voll Mark

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/7/26 8:00:05 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by RenovoRx Inc.

    10-K/A - RenovoRx, Inc. (0001574094) (Filer)

    5/15/26 5:25:44 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by RenovoRx Inc.

    10-Q - RenovoRx, Inc. (0001574094) (Filer)

    5/14/26 4:19:28 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RenovoRx, Inc. (0001574094) (Filer)

    5/14/26 4:17:07 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

    MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned UCLA surgeon and pancreatic disease expert Timothy Donahue, MD, to RenovoRx's scientific advisory board (SAB). Dr. Donahue is a nationally recognized expert in pancreatic cancer and serves as the Director of UCLA's Agi Hirshberg Center for Pancreatic Diseases and as Chief of the Division of Surgical Oncology at the David Geffen School of Medicine. He also holds the Garry Shandling Ch

    11/6/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RenovoRx Inc. (Amendment)

    SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

    2/14/23 4:51:34 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    4/14/22 2:24:24 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by RenovoRx Inc.

    SC 13G - RenovoRx, Inc. (0001574094) (Subject)

    2/14/22 6:33:04 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RNXT
    Financials

    Live finance-specific insights

    View All

    RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter

    Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled by the RenovoCath® Device Phase III TIGeR-PaC Trial Advances Toward Completion with Full Enrollment Expected in June 2026 Ended First Quarter with $12.4 million in cash, Sufficient to Fund Operations into at Least the Second Half of 2027 Management to Host Conference Call Today at 4:30 P.M. ET MOUNTAIN VIEW, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncolo

    5/14/26 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET

    MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/. During the call, RenovoRx's management is expected to highlight positive commercial momentum, including progress in achieved sales of RenovoCath as a stan

    4/29/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

    RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f

    3/30/26 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care